Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sieben

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Electroencephalography and Clinical Neurophysiology|April 1, 1994
Differences in the handling of the EMG examination at seven European laboratoriesB Johnsen, A Fuglsang-Frederiksen, S Vingtoft, et al.
Acta Psychiatrica Scandinavica. Supplementum|January 1, 1990
Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in BelgiumG Beckers, A Vereecken, E de Bleeker, et al.
The American Journal of Pathology|March 26, 2003
Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumorsNathalie L G Sieben, Sandra M Kolkman-Uljee, Adrienne M Flanagan, et al.
The Journal of Pathology|November 11, 2008
E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomasT De Meyer, I T G W Bijsmans, K K Van de Vijver, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behaviorMarjolijn B Verbruggen, Nathalie L G Sieben, Guido M J M Roemen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumorsNathalie L G Sieben, Jan Oosting, Adrienne M Flanagan, et al.
The Journal of Pathology|March 3, 2004
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumoursNathalie L G Sieben, Patricia Macropoulos, Guido M J M Roemen, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Electroencephalography and Clinical Neurophysiology|April 1, 1994
Differences in the handling of the EMG examination at seven European laboratoriesB Johnsen, A Fuglsang-Frederiksen, S Vingtoft, et al.
Acta Psychiatrica Scandinavica. Supplementum|January 1, 1990
Moclobemide versus amitriptyline in the treatment of depression: two small double-blind multicentre studies in BelgiumG Beckers, A Vereecken, E de Bleeker, et al.
The American Journal of Pathology|March 26, 2003
Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumorsNathalie L G Sieben, Sandra M Kolkman-Uljee, Adrienne M Flanagan, et al.
The Journal of Pathology|November 11, 2008
E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomasT De Meyer, I T G W Bijsmans, K K Van de Vijver, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behaviorMarjolijn B Verbruggen, Nathalie L G Sieben, Guido M J M Roemen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumorsNathalie L G Sieben, Jan Oosting, Adrienne M Flanagan, et al.
The Journal of Pathology|March 3, 2004
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumoursNathalie L G Sieben, Patricia Macropoulos, Guido M J M Roemen, et al.
Pageof 3